Nuvation Bio Inc. 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 6, 2026, reports on events occurring on June 30, 2026, and July 6, 2026. Nuvation Bio Inc. (NUVB) completed a registered underwritten public offering of convertible senior notes and subsequently exercised an over-allotment option (Greenshoe) to issue additional notes.
Key Financial Metrics and Capital Structure
- Debt Issuance: The Company issued $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032. This includes the initial $250.0 million offering plus a full $37.5 million over-allotment exercise.
- Net Proceeds: Estimated net proceeds from the total offering are approximately $277.6 million after underwriting discounts, commissions, and offering expenses.
- Interest Rate: 0.75% per year, payable semiannually in arrears beginning January 1, 2027.
- Maturity Date: July 1, 2032.
- Use of Proceeds: Approximately $2.2 million from the Greenshoe proceeds was used to fund additional capped call transactions. Remaining proceeds are designated for general corporate purposes, including working capital, operating expenses, and capital expenditures.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins as this is a transaction-specific report.
Material Changes and Transaction Details
The primary material change is the increase in long-term debt obligations and the associated hedging strategy.
- Greenshoe Exercise: Underwriters elected to exercise the full 30-day option to purchase an additional $37.5 million of Notes on July 6, 2026.
- Capped Call Transactions: The Company entered into additional capped call transactions to offset potential dilution from the Notes conversion. The cap price is initially set at $10.4580 per share, representing an 80.0% premium over the last reported sale price on June 25, 2026.
- Conversion Terms: Holders may convert Notes under specific conditions related to the trading price of Class A common stock or upon specified corporate events. Full conversion rights are available on or after April 1, 2032.
Outlook, Risks, and Management Commentary
Management expects to utilize the remaining net proceeds for general corporate purposes. The filing includes standard forward-looking statements regarding the use of proceeds, noting that actual results may differ due to market risks and conditions. The Company references its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, for a detailed discussion of risk factors.
Investor Verification Checklist
- Verify the final net proceeds received after all transaction costs are settled.
- Review the specific terms of the capped call transactions to understand the dilution protection limits.
- Monitor the Company's Class A common stock price relative to the conversion price and the $10.4580 cap price.
- Confirm the impact of the new debt on the Company's liquidity and future interest payment obligations starting in 2027.
- Check subsequent filings for any updates on the use of proceeds or changes in the Company's capital structure.